Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 110, Issue 38, Pages 15389-15394
Publisher
Proceedings of the National Academy of Sciences
Online
2013-09-04
DOI
10.1073/pnas.1313857110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
- (2015) Christel Larbouret et al. NEOPLASIA
- Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
- (2013) D. A. Ferraro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EGF Receptor Signaling Is Essential for K-Ras Oncogene-Driven Pancreatic Ductal Adenocarcinoma
- (2012) Carolina Navas et al. CANCER CELL
- Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
- (2012) Andrew V. Biankin et al. NATURE
- A monoclonal antibody to the human HER3 receptor inhibits Neuregulin 1-beta binding and co-operates with Herceptin in inhibiting the growth of breast cancer derived cell lines
- (2011) Edith Blackburn et al. BREAST CANCER RESEARCH AND TREATMENT
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer Statistics, 2010
- (2010) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Oncogenic KRas Suppresses Inflammation-Associated Senescence of Pancreatic Ductal Cells
- (2010) Kyoung Eun Lee et al. CANCER CELL
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
- (2010) M. W. Pedersen et al. CANCER RESEARCH
- Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling
- (2010) J. B. Spangler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Pertuzumab increases epidermal growth factor receptor down-regulation by counteracting epidermal growth factor receptor-ErbB2 heterodimerization
- (2009) J. B. Hughes et al. MOLECULAR CANCER THERAPEUTICS
- Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
- (2009) T. Ben-Kasus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Systems Biology of Growth Factor-Induced Receptor Endocytosis
- (2008) Yaara Zwang et al. TRAFFIC
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started